

Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: results of a 5-year, open-label extension study

Messoud Ashina,¹ Peter J Goadsby,² Uwe Reuter,³ Stephen Silberstein,⁴ David W Dodick,⁵ Fei Xue,⁶ Feng Zhang,⁶ Sunfa Cheng,⁶ Denise E Chou,⁶ Gabriel Paiva da Silva Lima⁶

¹Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; ²NIHR-Wellcome Trust King's Clinical Research Facility, King's College, London, UK; ³Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; ⁴Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA; ⁵Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA; ⁶Amgen Inc., Thousand Oaks, CA, USA

Migraine Trust Virtual Symposium, 3–9 October, 2020


This study was supported by Amgen, Thousand Oaks CA. Erenumab is co-developed by Amgen and Novartis.

Medical writing support was provided by Jon Nilsen, PhD (Amgen). The final responsibility for the content lies with the authors.



Double-blind treatment phase

Open-label treatment phase




Safety assessed Y1-5; efficacy assessed Y1, protocol amendment reinstated efficacy data collection during Y4-5. Majority of patients female (79%) and white (92%). Mean (SD) age 41.3 (10.9) years with mean duration of disease 20.9 (11.9) years.



Results


Change in monthly migraine days



Response at year 5 of open-label treatment phase

- Baseline monthly migraine days: 8.7 (0.2) days
- Mean change from baseline: -5.3 (0.3) days
- 69.3% $\geq 50\%$ response
- 48.2% $\geq 75\%$ response
- 35.8% 100% response

Change in monthly acute migraine-specific medication days





Response at year 5 of open-label treatment phase

- Baseline monthly AMSM days: 6.2 (0.2) days
- Mean change from baseline: -4.4 (0.3) days

Data represent mean (SE) change from double-blind treatment phase baseline. Year 5 represents the last 4-week period at week 268. AMSM data is from AMSM baseline users only. AMSM, acute migraine-specific medication



Exposure-adjusted patient incidence rates of adverse events



SAEs reported by >1 patient† (OLTP):

Ligament rupture, osteoarthritis, uterine leiomyoma, adjustment disorder, syncope, appendicitis, deep vein thrombosis, breast cancer

†Ligament rupture: n = 3; 0.2/100 PY; other SAEs: n = 2; 0.1/100 PY

Conclusions

- Long-term erenumab treatment (5 years; median exposure of 255 weeks) demonstrated sustained efficacy, including reductions in migraine frequency and monthly acute migraine-specific medication-use days.
- No new safety signals were detected in erenumab-treated patients over the 5-year extended treatment period.